Hypothesis

Specific probiotic strains that produce gamma‑aminobutyric acid (GABA) or stimulate host GABA synthesis via vagal afferent signaling will exert superior antidepressant effects compared to non‑GABA‑producing strains, and this effect will be predictable from baseline fecal microbiota signatures enriched for GABA‑metabolizing pathways.

Mechanistic Rationale

Recent meta‑analyses show probiotics outperform prebiotics in depression (SMD: –0.96) [1] and single‑strain formulations often excel [1]. Certain Lactiplantibacillus plantarum strains, such as Lp815, improve anxiety and sleep in placebo‑controlled trials [2], suggesting strain‑specific mechanisms. We propose that GABA‑producing probiotics increase intestinal luminal GABA, which activates vagal afferents expressing GABA_B receptors, thereby enhancing parasympathetic tone and dampening HPA‑axis activity [3]. Concurrently, baseline microbiota enriched for glutamate decarboxylase (GAD) genes may reflect a host environment primed to amplify this signal, explaining why personalized microbiome profiling predicts probiotic response in depression [3]. This mechanistic link extends beyond the observed correlation by positing a causal neuroimmune pathway.

Testable Predictions

1. In a double‑blind, placebo‑controlled RCT of adults with major depressive disorder, participants receiving a GABA‑producing strain (e.g., Lp815) will show a greater reduction in HAM‑D scores after 8 weeks than those receiving a non‑GABA‑producing control strain, with an expected SMD of at least –0.6.
2. Baseline fecal metagenomic abundance of GAD‑encoding genes will positively correlate with magnitude of depressive symptom improvement in the GABA‑producing strain arm (Spearman ρ ≥ 0.3, p < 0.05).
3. Pharmacological vagal blockade (e.g., low‑dose atropine) administered concurrently will attenuate the antidepressant benefit of the GABA‑producing strain, bringing outcomes equivalent to placebo.

Potential Confounders and Mitigation

• Dietary GABA intake will be monitored and standardized via food diaries.
• Antibiotic or probiotic use in the prior 3 months will be an exclusion criterion.
• Hormonal status (e.g., menstrual phase) will be recorded and included as a covariate, given known sex‑specific effects [5].

Falsifiability

If the GABA‑producing strain fails to outperform the control strain, or if baseline GAD abundance does not predict treatment response, or if vagal blockade does not diminish the effect, the hypothesis would be falsified.

References

[1] https://academic.oup.com/nutritionreviews/article/83/7/e1504/7934047 [2] https://doi.org/10.1101/2025.04.14.25325830 [3] https://pmc.ncbi.nlm.nih.gov/articles/PMC12689588/ [4] https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2023.1234549/full [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC12652156/